Table 25.1.

Nanoparticulate Systems Combining Antibody With Chemotherapeutic Agents

System	Antibody	Loaded Drug	Pathology/Target	Reference
PEG liposomes	Anti-MT1-MP(Fab′)	Doxorubicin	—	Hatakeyama et al. (2007)
Fe3O4/Au magnetic/gold nanoparticles	Bevacizumab anti-VEGF antibody	Doxorubicin	—	Ramos-Tejada et al. (2015)
Liposomes	Anti-HER2 monoclonal antibodies (trastuzumab)	Doxorubicin	Tumor xenograft nude mouse models	Banerjee et al. (2011); Park et al. (2007)
Chitosan nanoparticles	Anti-HER2 monoclonal antibodies	Doxorubicin	Cancer therapy (breast, ovary)	Yousefpour et al. (2011)
Human albumin serum (HAS) protein-based nanoparticle	Trastuzumab	Doxorubicin	Breast cancer therapy	Anhorn et al. (2008)
Chitosan scaffold-PLGA nanoparticles	Bevacizumab anti-VEGF antibody	5-Fluorouracil	Brain cancer	Kutlu et al. (2014)
Poly(propylene imine) dendrimer	Primary antibody (mAbK1)	Paclitaxel	Ovarian cancer therapy	Jain et al. (2015)
PLGA nanoparticles	Cetuximab	Paclitaxel palmitate	Lung cancer therapy	Karra et al. (2013)
Poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles	Trastuzumab	Paclitaxel	Breast cancer therapy	Sun et al. (2008)
Micellar nanoparticles (vitamin E TPGS and TPGS-siRNA)	AntiHER2 antibody	Docetaxel	Breast cancer therapy	Zhao et al. (2013); Mi et al. (2013)
Polylactide (PLA)-based nanoparticles	AntiHER2 antibody	Docetaxel	Breast cancer therapy	Zhao et al. (2012)
Poly(lactide-co-glycolide) (PLGA) nanoparticles	IgG Isotype control antibody anti-Fas mAb	Camptothecin	Colorectal cancer therapy	McCarron et al. (2008)
Liposomes	Antibody fragments scFv antibodies	Topotecan	Prostate cancer therapy	Roth et al. (2007)